Aptinyx To Forge Ahead With Pivotal PTSD Study
Exploratory Data Look Good
Executive Summary
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.